New drug cocktail targets Hard-to-Treat brain tumors
NCT ID NCT03922555
First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This early-stage trial is testing a drug called ASTX727 in adults with a type of brain tumor (glioma) that has an IDH mutation and has come back or is growing. The drug combines two substances to try to stop cancer cells from growing. The main goal is to find the highest safe dose, with 18 participants enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ASTX727 (cedazuridine and decitabine)
- What this could lead to
- If it works, this could point toward a new treatment option for people with recurrent IDH-mutant gliomas, potentially slowing tumor growth.
- What could go wrong
- This is a very early Phase 1 trial with only 18 participants, focused on finding a safe dose. It is not yet known if ASTX727 will effectively control the cancer, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROLOGICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
-
Massachusetts General Hospital Cancer Center
RECRUITINGBoston, Massachusetts, 02114, United States